Rapid and selective generation of H 2 S within mitochondria protects against cardiac ischemia-reperfusion injury.

Autor: Miljkovic JL; MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, CB2 0XY, UK., Burger N; MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, CB2 0XY, UK., Gawel JM; School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UK., Mulvey JF; Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK., Norman AAI; School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UK., Nishimura T; Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK; Innovative Biology Laboratories, Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, 251-8555, Japan., Tsujihata Y; Innovative Biology Laboratories, Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, 251-8555, Japan., Logan A; MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, CB2 0XY, UK., Sauchanka O; Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK., Caldwell ST; School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UK., Morris JL; MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, CB2 0XY, UK., Prime TA; MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, CB2 0XY, UK., Warrington S; School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UK., Prudent J; MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, CB2 0XY, UK., Bates GR; MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, CB2 0XY, UK., Aksentijević D; Centre for Biochemical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, United Kingdom., Prag HA; MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, CB2 0XY, UK; Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK., James AM; MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, CB2 0XY, UK., Krieg T; Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK., Hartley RC; School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UK. Electronic address: Richard.Hartley@glasgow.ac.uk., Murphy MP; MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge Biomedical Campus, CB2 0XY, UK; Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK. Electronic address: mpm@mrc-mbu.cam.ac.uk.

Publikováno v: Redox biology [Redox Biol] 2022 Sep; Vol. 55, pp. 102429. Date of Electronic Publication: 2022 Aug 05.

Anti-Inflammatory and Antinociceptive Properties of the Quercetin-3-Oleate AV2, a Novel FFAR1 Partial Agonist.

Autor: Pessina, Federica¹ (AUTHOR) alessandra.gamberucci@unisi.it, Casini, Ilenia² (AUTHOR) ilenia.casini@student.unisi.it, Gamberucci, Alessandra¹ (AUTHOR) cinzia.signorini@unisi.it, Carullo, Gabriele³ (AUTHOR) gabriele.carullo@unisi.it, Signorini, Cinzia¹ (AUTHOR), Brizzi, Antonella³ (AUTHOR) federica.pessina@unisi.it, Aiello, Francesca⁴ (AUTHOR) francesca.aiello@unical.it, Aloisi, Anna Maria² (AUTHOR) annamaria.aloisi@unisi.it, Pieretti, Stefano⁵ (AUTHOR) stefano.pieretti@iss.it

Publikováno v: International Journal of Molecular Sciences. Nov2024, Vol. 25 Issue 21, p11635. 16p.

Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach.

Autor: Kamaura M; Cardiovascular & Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Kubo O; Cardiovascular & Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: osamu.kubo@takeda.com., Sugimoto H; Cardiovascular & Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Noguchi N; Cardiovascular & Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Miyashita H; Cardiovascular & Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Abe S; Cardiovascular & Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Matsuda K; Cardiovascular & Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Tsujihata Y; Cardiovascular & Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Odani T; Biomolecular Research Laboratories, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Iwasaki S; DMPK Research Laboratories, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Murata T; Cardiovascular & Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan., Sato K; Cardiovascular & Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.

Publikováno v: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2021 Mar 15; Vol. 34, pp. 116034. Date of Electronic Publication: 2021 Jan 23.

TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats

Autor: Ito, R, Tsujihata, Y, Matsuda-Nagasumi, K, Mori, I, Negoro, N, Takeuchi, K

TAK-875, a selective GPCR40/free fatty acid receptor 1 agonist, improves glycaemic control by increasing glucose-dependent insulin secretion. Metformin is a first-line drug for treatment of type 2 diabetes that improves peripheral insulin resistance.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8f6ccca38c62f99a972f9669f672088d
https://europepmc.org/articles/PMC3791995/

GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.

Autor: Ueno H; Cardiovascular Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Ito R; Cardiovascular Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Abe SI; Cardiovascular Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Ogino H; Cardiovascular Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Maruyama M; Cardiovascular Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Miyashita H; Cardiovascular Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Miyamoto Y; Cardiovascular Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Moritoh Y; Research and Development Division, SCOHIA PHARMA Inc., Kanagawa, Japan., Tsujihata Y; Cardiovascular Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Takeuchi K; Cardiovascular Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan., Nishigaki N; Cardiovascular Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan.

Publikováno v: PloS one [PLoS One] 2019 Sep 16; Vol. 14 (9), pp. e0222653. Date of Electronic Publication: 2019 Sep 16 (Print Publication: 2019).